Ocelot Bio Overview
- Year Founded
-
2020
- Status
-
Out of Business
- Employees
-
14
- Latest Deal Type
-
Out of Business
Ocelot Bio General Information
Description
Operator of a biopharmaceutical company intended to help patients with severe liver disease. The company's therapeutic peptide selectively addresses portal hypertension-induced complications of end-stage liver disease (ESLD), enabling patients to overcome the serious consequences associated with complications of portal hypertension.
Contact Information
Website
www.ocelotbio.comCorporate Office
- 601 Marshall Street
- Redwood City, CA 94063
- United States
Corporate Office
- 601 Marshall Street
- Redwood City, CA 94063
- United States
Ocelot Bio Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Out of Business | 20-Dec-2024 | Completed | Out of Business | |||
| 2. Early Stage VC | 12-Jul-2023 | Completed | Clinical Trials - Phase 2 | |||
| 1. Early Stage VC (Series A) | 13-Apr-2021 | $36M | $36M | Completed | Clinical Trials - Phase 2 |
Ocelot Bio Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A |
Ocelot Bio Comparisons
Industry
Financing
Details
Ocelot Bio Competitors (2)
One of Ocelot Bio’s 2 competitors is Ardelyx, a Formerly VC-backed company based in Waltham, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Ardelyx | Formerly VC-backed | Waltham, MA | ||||
| Akebia Therapeutics | Formerly VC-backed | Cambridge, MA |
Ocelot Bio Patents
Ocelot Bio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2024073445-A1 | Mixed vasopressin receptor agonist-antagonist for modulating mean arterial pressure | Inactive | 30-Sep-2022 | ||
| WO-2024073451-A1 | Mixed vasopressin receptor agonist-antagonist for treating end-stage liver disease and complications associated thereof | Inactive | 30-Sep-2022 | ||
| WO-2023183339-A1 | Selective vasopressin receptor agonist for end-stage liver disease | Inactive | 22-Mar-2022 | ||
| US-20160122386-A1 | V1a receptor agonists | Active | 05-Nov-2014 | ||
| US-9388214-B2 | V1a receptor agonists | Active | 05-Nov-2014 | C07K7/06 |
Ocelot Bio Signals
Ocelot Bio FAQs
-
When was Ocelot Bio founded?
Ocelot Bio was founded in 2020.
-
Where is Ocelot Bio headquartered?
Ocelot Bio is headquartered in Redwood City, CA.
-
What is the size of Ocelot Bio?
Ocelot Bio has 14 total employees.
-
What industry is Ocelot Bio in?
Ocelot Bio’s primary industry is Drug Discovery.
-
Is Ocelot Bio a private or public company?
Ocelot Bio is a Private company.
-
What is Ocelot Bio’s current revenue?
The current revenue for Ocelot Bio is .
-
How much funding has Ocelot Bio raised over time?
Ocelot Bio has raised $39M.
-
Who are Ocelot Bio’s competitors?
Ardelyx and Akebia Therapeutics are competitors of Ocelot Bio.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process